8-KLeadership ChangesAcquisitions & DispositionsFinancial Events+4

Merck & Co., Inc. 8-K Report, Acquisition Completed (Nov 4, 2009)

Filed November 4, 2009For Securities:MRK

Summary

This Form 8-K from Merck & Co., Inc. (MRK) reports on the completion of the merger between Merck & Co., Inc. ("Old Merck") and Schering-Plough Corporation ("Schering-Plough") on November 3, 2009. The transaction, structured as a merger of equals, resulted in Schering-Plough being renamed "Merck & Co., Inc." (referred to as "New Merck"), with Old Merck becoming a wholly-owned subsidiary named Merck Sharp & Dohme Corp. This filing details the significant corporate changes, including the conversion of shares, the assumption and guarantee of debt obligations from both entities, changes in executive leadership and board composition, and updates to various compensation and ethics policies. For investors, the key takeaway is the official closing of this transformative merger, creating a larger, combined pharmaceutical entity. The document outlines the stock exchange ratio, the executive team appointments, and the governance changes. It also addresses the financial implications of the merger, such as the consolidation of debt and credit facilities, and the ongoing management of incentive plans and director compensation in the newly formed company. Investors should note the details regarding the integration of Schering-Plough's operations and obligations into the new Merck structure.

Key Highlights

  • 1Completion of the merger between Merck & Co., Inc. and Schering-Plough Corporation on November 3, 2009.
  • 2Schering-Plough was renamed Merck & Co., Inc. (New Merck), and Old Merck became a subsidiary named Merck Sharp & Dohme Corp.
  • 3Schering-Plough shareholders received $10.50 cash and 0.5767 shares of New Merck common stock per share.
  • 4New Merck assumes guarantees for existing debt obligations of both Old Merck and Schering-Plough, totaling billions of dollars.
  • 5Significant changes in executive leadership and board of directors, with key personnel from Old Merck appointed to lead New Merck.
  • 6Adoption of a new Code of Conduct and updates to various director and executive compensation plans and policies.
  • 7New Merck authorized to issue 6.5 billion shares of common stock and 20 million shares of preferred stock.

Frequently Asked Questions

Upon completion of the merger, New Merck became responsible for and guaranteed the outstanding debt of both Old Merck and Schering-Plough. This includes approximately $8.31 billion in Old Merck Notes and significant debt from Schering-Plough, as detailed in the filing.

Richard T. Clark was appointed Chairman, President, and CEO of New Merck. Peter N. Kellogg was appointed Executive Vice President and Chief Financial Officer, and John Canan was appointed Senior Vice President and Controller. These individuals previously held similar roles at Old Merck.

Existing equity awards from both Old Merck and Schering-Plough were assumed by New Merck and adjusted based on the merger consideration. The filing details how stock options, restricted stock units, and performance share units are treated under the new corporate structure.

The merger resulted in a combined Board of Directors, with some directors from Schering-Plough continuing to serve alongside those from Old Merck. New corporate bylaws and a certificate of incorporation were adopted for the merged entity, and a new Code of Conduct was implemented.